Relative seizure reduction was as equally strong a predictor of patient quality of life after epilepsy surgery as seizure freedom in a recent study, with absolute reduction proving to be the worst model surveyed.
In an interview with NeurologyLive, Dennis Lal, PhD, discusses the value of genetic testing and how it can optimize the way we develop clinical trials and test new therapies. 

SAP Partner Banner